原發性免疫力缺乏藥物市場規模、佔有率、成長分析（按適應症、藥物類別、給藥途徑、年齡層、分銷管道和地區）—2025 年至 2032 年產業預測

2023 年全球原發性免疫力缺乏藥物市場規模為 28 億美元，預計將從 2024 年的 29.6 億美元成長到 2032 年的 46.1 億美元，預測期內（2025-2032 年）的複合年成長率為 5.7%。

全球原發性免疫力缺乏(PI) 藥物市場正呈現溫和擴張態勢，這得益於人們認知度的提高、診斷技術的改進以及個性化治療機會的增加。約有 450 種長期罕見疾病被歸類為原發性免疫力缺乏缺陷，這些疾病是由影響免疫反應的基因缺陷引起的，因此對免疫球蛋白替代療法、靶向生技藥品和幹細胞移植等長期治療的需求日益成長。基因技術和篩檢方法的進步促進了早期診斷，進一步增加了這種需求。北美和歐洲的監管機構已將罕見藥物的開發列為優先事項，增加了對新藥的投資。此外，根據國家罕見疾病舉措指定 PI 疾病將獲得資金並減少治療障礙，而病患權益倡導和官民合作關係對於改善藥物可近性至關重要，尤其是在發展中地區。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

原發性免疫力缺乏缺陷症藥物市場規模（按適應症和複合年成長率） (2025-2032)

• 市場概覽
• 無法分類的免疫力缺乏（CVID）
• X連鎖無丙種球蛋白血症（XLA）
• 嚴重複合型免疫力缺乏症（SCID）
• 威斯科特-奧爾德里奇症候群（WAS）
• 高IgM症候群（HIGM）

原發性免疫力缺乏缺陷症藥物市場規模（依藥物類別和複合年成長率） (2025-2032)

• 市場概覽
• 免疫球蛋白替代療法
• 免疫調節劑
• 幹細胞療法
• 基因治療
• 抗生素

原發性免疫力缺乏藥物市場規模（依給藥途徑及複合年成長率）（2025-2032）

• 市場概覽
• 靜脈注射（IV）
• 皮下（SC）
• 肌肉注射（IM）

原發性免疫力缺乏缺陷症藥物市場規模（按年齡層分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 孩子們
• 成人

原發性免疫力缺乏藥物市場規模（依分銷管道分類）及複合年成長率（2025-2032）

• 市場概覽
• 醫院
• 專業藥房
• 網路藥局

原發性免疫力缺乏缺陷症治療市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• CSL Behring（USA）
• Grifols（Spain）
• Octapharma（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• Biotest AG（Germany）
• ADMA Biologics（USA）
• Bio Products Laboratory（BPL）（USA）
• LFB SA（France）
• Kedrion Biopharma SpA（Italy）
• Pfizer Inc.（USA）
• Orchard Therapeutics（UK）
• Rocket Pharmaceuticals（USA）
• Bluebird Bio（USA）
• China Biologic Products Holdings（China）
• GC Pharma（South Korea）
• Baxter International Inc.（USA）
• X4 Pharmaceuticals（USA）
• Novartis AG（Switzerland）
• Sanofi SA（France）
• Bristol Myers Squibb（USA）

結論和建議

Global Primary Immunodeficiency Therapeutics Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 2.96 billion in 2024 to USD 4.61 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The global primary immunodeficiency (PI) therapeutics market is witnessing a gradual expansion, driven by increased awareness, improved diagnostics, and enhanced access to tailored treatments. With around 450 rare long-term disorders classified as primary immunodeficiencies resulting from genetic defects affecting immune responses, there is a rising need for long-term therapies like immunoglobulin replacement, targeted biologics, and stem cell transplants. Advances in genetic technologies and screening methods have facilitated earlier diagnoses, further fueling this demand. Regulatory bodies in North America and Europe are prioritizing orphan drug development, resulting in heightened investment in new medications. Additionally, the designation of PI diseases as national rare disease initiatives is attracting funding and reducing treatment barriers, while patient advocacy and public-private partnerships are essential in improving access, especially in developing regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Primary Immunodeficiency Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Primary Immunodeficiency Therapeutics Market Segments Analysis

Global Primary Immunodeficiency Therapeutics Market is segmented by Indication, Drug Class, Route of Administration, Age Group, Distribution Channel and region. Based on Indication, the market is segmented into Common Variable Immunodeficiency (CVID), X-linked Agammaglobulinemia (XLA), Severe Combined Immunodeficiency Disorders (SCID), Wiskott-Aldrich Syndrome (WAS) and Hyper-IgM Syndrome (HIGM). Based on Drug Class, the market is segmented into Immunoglobulin Replacement Therapy, Immune-modulating Agents, Stem Cell Therapy, Gene Therapy and Antibiotics. Based on Route of Administration, the market is segmented into Intravenous (IV), Subcutaneous (SC) and Intramuscular (IM). Based on Age Group, the market is segmented into Pediatric and Adult. Based on Distribution Channel, the market is segmented into Hospitals, Specialty Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Primary Immunodeficiency Therapeutics Market

Recent advancements in diagnostic technologies, particularly next-generation sequencing (NGS) and genetic screening, have substantially reduced the time needed to diagnose primary immunodeficiency (PI) diseases. Early diagnosis enables prompt initiation of treatment, leading to improved therapeutic outcomes by minimizing infection burdens. This heightened diagnostic accuracy enhances the management of PI, fosters greater patient compliance, and ultimately boosts quality of life. As a result, there is a growing demand for PI therapeutics in the market. The positive correlation between early diagnosis and effective treatment underscores the critical role of advanced diagnostics in driving growth within the global primary immunodeficiency therapeutics market.

Restraints in the Global Primary Immunodeficiency Therapeutics Market

A significant challenge facing the global primary immunodeficiency therapeutics market is the high cost associated with immunoglobulin therapies, gene treatments, and stem cell therapies. This financial burden is particularly acute in low-income countries, where patients struggle to afford crucial, potentially life-saving treatments. Additionally, rising expenses related to plasma collection have further inflated the costs of immunoglobulin therapies, a trend observed even in developed nations. These financial obstacles contribute to increasing reimbursement difficulties, ultimately restricting patient access to these therapies and making it challenging for healthcare systems to establish and sustain long-term treatment regimens effectively.

Market Trends of the Global Primary Immunodeficiency Therapeutics Market

The Global Primary Immunodeficiency (PI) Therapeutics market is witnessing a transformative trend driven by the integration of artificial intelligence (AI) into individualized immunoglobulin dosing. This cutting-edge approach tailors treatment based on specific patient parameters, such as weight, infection frequency, and metabolic rate, thereby optimizing therapeutic regimens and mitigating side effects. By enhancing treatment adherence and maximizing resource efficiency, AI is poised to redefine patient care in the PI sector. Ongoing clinical trials aim to validate these innovative dosing algorithms across diverse populations, signaling a pivotal shift towards more personalized medicine that could significantly improve patient outcomes, driving market growth in this segment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Primary Immunodeficiency Therapeutics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Common Variable Immunodeficiency (CVID)
• X-linked Agammaglobulinemia (XLA)
• Severe Combined Immunodeficiency Disorders (SCID)
• Wiskott-Aldrich Syndrome (WAS)
• Hyper-IgM Syndrome (HIGM)

Global Primary Immunodeficiency Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Immunoglobulin Replacement Therapy
• Immune-modulating Agents
• Stem Cell Therapy
• Gene Therapy
• Antibiotics

Global Primary Immunodeficiency Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous (IV)
• Subcutaneous (SC)
• Intramuscular (IM)

Global Primary Immunodeficiency Therapeutics Market Size by Age Group & CAGR (2025-2032)

• Market Overview
• Pediatric
• Adult

Global Primary Immunodeficiency Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Pharmacies
• Online Pharmacies

Global Primary Immunodeficiency Therapeutics Market Size & CAGR (2025-2032)

• North America (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
  • US
  • Canada
• Europe (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• CSL Behring (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADMA Biologics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory (BPL) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rocket Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GC Pharma (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• X4 Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations